The fundamental premise remains unvalidated despite extensive mechanistic speculation. Independent validation using purified proteins and orthogonal binding assays is essential before pursuing mechanistic studies. This determines whether any C1q-related effects are direct or indirect.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e (Analysis: SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e)
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
MECH 7CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Structure-activity relationship (SAR) analysis is …
Circular reasoning: scaffold-specific binding indicates true pharmacophores while shared binding indicates artifact - but this distinction is not absolute
Negative results are ambiguous: other ALK inhibitors failing to show C1q binding could indicate unique pharmac…▼
Negative results are ambiguous: other ALK inhibitors failing to show C1q binding could indicate unique pharmacophore OR assay conditions favoring alectinib's specific formulation
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Hypothesis 1: Alectinib Indirectly Modulates C1q via ALK Signaling in Tumor-Associated Macrophages
Description: Rather than binding C1q directly, alectinib may suppress C1q production through ALK-independent inhibition of NF-κB signaling in tumor-associated macrophages (TAMs), thereby reducing complement-mediated pro-tumor inflammation.
C1q is produced by macrophages and myeloid cells in the tumor microenvironment
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Alectinib-C1q Binding Hypotheses
Hypothesis 1: Indirect Modulation via ALK Signaling in TAMs
Specific Weaknesses in Evidence
The proposed mechanism requires an implausibly specific chain of events: alectinib must cross tumor cell membranes, inhibit ALK in tumor cells, produce a signal that travels to TAMs, and there suppress NF-κB to reduce C1q transcription. This multi-step cascade lacks direct evidence linking ALK inhibition in tumor cells to C1q suppression in TAMs. The evidence cited for NF-κB cross-talk with complement regulation (PMID:28813421) descri
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Drug Development Perspective: Alectinib-C1q Binding Analysis
Executive Summary
The critical evaluation correctly identifies that orthogonal validation is essential before mechanistic elaboration. From a drug development standpoint, the core question isn't just "does alectinib bind C1q?" but rather "so what if it does?" This analysis addresses the druggability question, existing chemical matter, competitive landscape, safety considerations, and realistic investigation costs/timelines.
1. Target Druggability: Is C1q a Viable Therapeutic Target?
Current Status
C1
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼